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Project Summary 
 
Technical Abstract 
This Small Business Innovation Research Phase I project, presented by Talamo Inc., 
is to test an ovarian cancer therapeutic delivery system, comprised of a nanoscale 
biocompatible vesicle that carries a bioactive small interfering RNA molecule 
(siRNA), in vivio in mice. The siRNA has shown to reduce the expression of an 
enzyme (Sod2) that is highly expressed in multiple ovarian cancer types. The 
reduced expression of Sod2 will allow the tumor to become increasingly susceptible 
to chemotherapy agents, while simultaneously diminishing tumor progression. 
Research has proved that the nanoscale vesicle is non-toxic and in combination with 
siRNA effectively reduced Sod2 expression, in vitro, in ovarian cancer cells.  
 
Based upon these findings Talamo, Inc. plans to move forward to in vivo mice 
testing. It is necessary to prove that the nanoscale vesicle system is effective in 
inhibiting Sod2 expression and is also non-toxic in mice. The funds from phase I of 
this Small Business Innovation Research (SBIR) grant will allow Talamo, Inc. to 
proceed with in vivo mice testing. The anticipated results are that the mice given the 
therapy will have smaller tumors and lower Sod2 levels than the control group.  
 
Commercialization Abstract 
This neoadjuvant therapy has great commercial potential. Ovarian cancer is the 
deadliest of the gynecologic cancers. There will be 14,030 deaths in 2013 from 
ovarian cancer and ranks as the 10th most common cancer among women. This 
therapy would be administered to a patient as soon as she was diagnosed with 
ovarian cancer. Immediate therapy would slow the tumor progression and increase 
sensitivity to chemotherapy agents. This would allow physicians more time to 
proactively treat or to remove the tumors. Thus, the survival rates of patients with 
clear cell carcinoma will increase.  
 
Talamo Inc. has established conditional collaboration with Bristol-Myers Squibb, if 
the nanoscale delivery system is proven to be non-toxic and effective at inhibiting 
Sod2 in mice. Thus, it is imperative for Talamo, Inc. to be awarded this SBIR Phase I 
grant in order to fund in vivo mice testing. If the results from the in vivo mice testing 
prove favorable, Bristol-Myers Squibb will fund Phase 1 FDA clinical trials in 
conjunction with the $1,000,000 SBIR Phase II award. Once this therapy has been 
brought to market, after passing Phase 1-3 FDA clinical trials, Talamo Inc. will use 
its profits to fund future R&D for nanoscale delivery wesicles to be used to treat 
other cancers that also exhibit high levels of Sod2.  
 
Key Words 
Nanotechnology, Nanoparticle, Ovarian Cancer, Drug Delivery Systems, Drug 
Targeting, Neoadjuvant Therapy, Superoxide Dismutase-2, Bioglycogen, Taxol. 
 
Research Topic Biotech and drug delivery 
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Project Description: 
 
1. Identification and Significance of Opportunity 
 
Talamo Inc., has created a nanoparticle drug delivery system that in combination 
with current chemotherapy treatments will be able to better treat clear cell 
carcinoma ovarian cancer. After more research, we would like to use this nanoscale 
delivery system to treat other cell types. Our proposed therapy will result in slowed 
tumor progression and increased sensitivity to chemotherapy agents. By slowing 
the tumor progression, physicians will have additional time to successfully eradicate 
or remove the tumor. The tumor’s increased sensitivity of chemotherapy agents will 
make the chemotherapy treatments more efficient and will result in lower 
necessary dosages of chemotherapy. This novel treatment will result in decreasing 
the mortality rate of women afflicted with ovarian cancer, while simultaneously 
allowing these women to have a less painful treatment process.  
 
2. Background and Phase I Technical Objectives 
 
A. Ovarian Cancer Basics: 
 
Ovarian cancer forms in the tissues of the ovary in women. It accounts for 
approximately three percent of cancers in women. While the 10th most common 
cancer among women, ovarian cancer is the fifth leading cause of cancer-related 
death among women, and is the deadliest of gynecologic cancers. A woman’s lifetime 
risk of developing ovarian cancer is 1 in 72 and a woman’s lifetime risk of dying 
from ovarian cancer is 1 in 95. The relative five-year survival rate is 44%, survival 
rates vary depending on stage of diagnosis. [1] It is estimated that approximately 
$5.1 billion is spent in the United States each year on ovarian cancer treatment. [2]  
 
In 2013, in the United States, there will be 22,240 new cases of ovarian cancer and 
14,030 ovarian cancer related deaths. [2] Since the 1980s, the incidence rates have 
been declining due to modern chemotherapy technologies and surgery, however 
ovarian cancer still has the highest mortality rate of all cancers of the female 
reproductive system. (See Figure 1) This high mortality count is a result of a lack of 
early symptoms and of effective ovarian cancer screening tests. Thus, ovarian cancer 
is often diagnosed at an advanced stage. Only 15% of ovarian cancer patients are 
diagnosed early.  
 6 
 
  
 
  
 
 
 
The National Cancer Institute’s (NCI) 
investment in ovarian cancer research 
increased from $96.9 million in 2007 to 
$110.8 million in 2011. (See Figure 2) 
In addition to this funding, NCI 
supported $22 million in ovarian 
cancer research in 2009 and 2010 using 
funding from the American Recovery and Reinvestment Act (ARRA). [2] The federal 
government has recognized that ovarian cancer is an important area of scientific research 
to invest in. Thus, we believe that our company has a product with great market value, 
significance, and innovation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Superoxide Dismutase-2 
 
The most common form of ovarian cancer arises from the cells covering the surface 
of the ovary, known as epithelial carcinoma. There are five major types of epithelial 
carcinoma: carcinoma-serous, mucinous, endometrioid, clear cell and 
undifferentiated. [3] These types are then further divided into grades, depending on 
Figure 1: U.S. Ovarian Cancer 
Mortality-NIH: U.S. Department of 
Health and Human Services [2] 
Figure 2: NCI Ovarian 
Cancer Research 
Investment-NIH: U.S. 
Department of Health 
and Human Services [2] 
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how virulent they appear. Of these five, clear cell carcinoma and undifferentiated 
carcinoma have the poorest prognosis.  
 
Mitochondrial antioxidant enzyme superoxide dismutase-2 (Sod2) is an enzyme in 
humans that is a member of the iron/manganese superoxide dismutase family. An 
antioxidant is a molecule that inhibits the oxidation of other molecules. [4] This 
enzyme binds to the superoxide byproducts of oxidative phosphorylation and 
converts them to hydrogen peroxide and diatomic oxygen. (See Figure 3) 
 
 
 
 
 
 
 
 
Mutations in this enzyme have been associated with idiopathic cardiomyopathy 
(IDC), premature aging, sporadic motor neuron disease, and cancer. [4] Sod2 
overexpression in many instances enhances the metastatic phenotype that is 
reversed by efficient H2O2 scavenging. [5-6] Increased levels of Sod2 expression 
have been observed in ovarian cancer clear cell carcinoma when compared to the 
other 4 types of ovarian cancer. (See Figure 4) ES2 and TOV21G are two cell lines of 
clear cell carcinoma ovarian cancer that have higher levels of Sod2 than other 
ovarian cancer cells lines. (See Figure 5) All initial in vitro testing, performed by 
Talamo Inc., used these two cells lines. These increased levels of Sod2 expression 
have been linked to tumor progression and chemoresistance.  
                                               
  
Figure 4: Comparison of Sod2 levels between 
the five major types of ovarian cancer 
Figure 5: Comparison of Sod2 levels between 
different cell lines of ovarian cancer. CCC stands 
for clear cell carcinoma.  
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In order to slow the progression of tumor cells and to increase sensitivity to 
chemotherapy agents it will be necessary to focus on the down-regulation of Sod2 in 
ovarian cancer. The down-regulation of Sod2 will occur by transfection of small 
interfering RNA, siRNA, into ovarian cancer cells. siRNA is a class of double-stranded 
RNA molecules, 20-25 base pairs in length. siRNA’s main function is to play a role in 
RNA interference (RNAi) pathway, where it interferes with the expression of 
specific genes, in our experiments the knockdown of Sod2. [7] 
 
It was important to determine if the siRNA we used was inhibiting Sod2 expression 
or if our transfection agent was responsible for this inhibition. We compared three 
different siRNA types: scramble control, Sod2 siRNA #1, and Sod2 siRNA #2 in a 
protein expression gel experiment. We also added a mock control in order to prove 
that our transfection agent was not responsible for the Sod2 inhibition. When 
comparing the top row of the gel, the two bands under the siRNA #1 and siRNA #2 
are significantly smaller than the other two bands. The smaller band size shows that 
the Sod2 expression has decreased. (See Figure 6)  
 
We then imaged the effects of siRNA on spheroids. Multicellular spheroids are 
composed of tumor cells growing in 3-dimensional structure stimulating the growth 
and microenvironmental conditions of real tumors. Based on these images, Sod2 
siRNA #1 and Sod2 siRNA #2 performed a greater knockdown (reduction) of Sod2 
than the mock and scramble controls. (See Figure 7) From these image the effects of 
the different siRNAs on the microscale was compared. As we expected siRNA #1 and 
siRNA #2 broke down the spheroids while the mock and scramble controls had 
significantly less impact on the spheroids. The break down of these spheroids 
signifies a decrease in Sod2 expression. Thus, all of our experiments will use Sod2 
siRNA #1 and Sod2 siRNA #2 due to their ability to break down the spheroids.  
  
 
 
Figure 6: ES2 Sod2 Knockdown in protein 
expression gel 
Figure 7: Break down of spheroids-Images taken by an AMG Evos Fl 
microscope in phase contrast. 
Mock Scramble 
siRNA #1 siRNA #2 
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Transfected molecules Purpose 
siRNA #1 Experimental 
siRNA #2 Experimental 
Scramble Control siRNA intersects with a number of other 
pathways, so nonspecific effects can be 
triggered 
Mock Control Absence of siRNA 
Table 1: Transfected molecules-Break down of Spheroids 
 
After our initial observations of Sod2 expression in clear cell carcinoma, we begin to 
create a non-toxic nanoparticle, a vehicle that would be able to transport siRNA 
directly to the cancerous tumor. [8] We tested the toxicity by means of an MTT 
Assay of three potential vehicles: Phytoglycogen, Cluster Dextrin®, and 
BioglycogenTM. Our results proved that BioglycogenTM was the least toxic to ES2 and 
TOV21G cells and proved to be the ideal therapeutic nanocarrier (data not shown). 
 
C. Nanoparticle Delivery System-BioglycogenTM  
 
Nanoparticles have many potential benefits for drug delivery to targeted ovarian 
cancer cells. This study tested the ability of a nanoparticle to transport a complex 
molecular cargo, siRNA, to the clear cell carcinoma ovarian cancer. Most nanoscale 
vehicles have been derived from biological, organic or inorganic origins in an 
attempt to address a wide variety of biological mechanisms and targets. [9] 
 
BioglycogenTM is an α-D glucan dendrimer, branched glucose. It resembles natural 
phytoglycogen, which is extracted from corn. [10-11] It has low cytotoxicity, which 
is essential for a drug delivery vehicle. Since it is a derivative of glucose humans 
naturally have enzymes for its degradation. This is important so that the vehicle can 
be taken up by the cell and the siRNA can be released and allowed to inhibit the 
Sod2. [9, 12] The FDA has already approved of BioglycogenTM for food usage, so it 
should be easy to bring this neoadjuvant therapy to the market. BioglycogenTM is 
commercially available in large quantities and is more economical than many other 
available dendrites. BioglycogenTM is approximately $750/kg.  
 
In order for us to attach the siRNA to our BioglycogenTM nanoparticle it is necessary 
to modify our particle. [9] We have created two different modification methods: 
oxidation and charge conjugation. 
 
The purpose of our oxidation modification is to create aldehyde groups that will 
then be able to bind to the siRNA. [13] We oxidize our particle for 6 hours using 
sodium periodate, NaIO4. (Figure 7) The solution was then purified by dialysis 
against distilled water, dH2O. Finally, the sample was freeze-dried on a lypholizer. 
The aldehydes groups would then be bonded to an aminated siRNA. The oxidation 
was confirmed by using Fourier Transform Infrared Spectrometry (FTIR) and 
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Dynamic Light Scattering (DLS). This modified nanoparticle was proven to be taken 
up in ovarian cancer cells by fluorescence microscopy (data not shown).   
 
Figure 8: Oxidation of glucose polymer with sodium periodate, NaIO4. [13]  
 
The purpose of our charge conjugation modification is to introduce positive charge 
to the particle that will then be able to react with the siRNA. The BioglycogenTM 
particle was reacted overnight with glycidyltrimethylammonium chloride (GTMA). 
(Figure 8) We then purified our solution by dialysis against distilled water, dH2O. 
Finally, the sample was freeze-dried on lypholizer. The charge conjugation was 
confirmed by DLS. This modified nanoparticle was proven to be taken up in ovarian 
cancer cells by fluorescence microscopy (data not shown).   
 
Figure 9: Conjugation of BioglycogenTM with glycidyltrimethylammonium chloride (GTMA) 
 
Our previous studies have shown that our modified BioglycogenTM nanoparticles are 
more efficient and less toxic in delivering siRNA molecules than traditional RNAi 
transfection techniques such as Lipofectamine™ RNAiMAX (data not shown). 
 
Modification Methods Description 
Oxidation Introduce aldehyde to glucose units 
Reaction of aldehyde with aminated 
siRNA 
Charge Conjugation Introduce positive charge to particle 
Bind to siRNA with charge interaction  
 
 BG BG 
GTMA 
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Table 2: Summary of nanoparticle modification methods 
 
3. Phase 1 Research Plan: 
 
Previous studies have demonstrated that our modified BioglycogenTM nanoparticle 
is non-toxic and effective at inhibiting Sod2 expression in vitro in clear cell 
carcinoma ovarian cancer cells. Before we can proceed to FDA clinical trials in 
humans, we must first prove that our results in vitro are consistent with in vivo 
mice testing. We will be performing these in vivo mouse tests for a 6-month period. 
Since we are researching ovarian cancer, we must use female mice.  
 
Task 1: 
 
During the first two weeks we will inject the BioglycogenTM modified nanoparticles, 
without siRNA, to healthy mice, via the intraperitoneal cavity, to observe their 
reactions to the particle. During the in vitro studies two different nanoparticle 
modifications were synthesized. Both of these modifications will be tested alone in 
the mice. In order to proceed to the next experiment, these mice must not exhibit 
any abnormal behavior. We will observe their behaviors such as eating/drinking 
patterns, weight loss, activity, and blood levels. As long as all of these criteria are 
met and the mice caregiver does not have any concerns, we can conclude that the 
particle is non-toxic to the mice.  
 
Task 2: 
 
After proving that the particle itself is non-toxic to the mice, we can proceed to test 
whether our particle will inhibit the Sod2 levels, resulting in slowed tumor 
progression and increased chemosensitivity, in the mice. First, we will 
intraperitoneally inoculate the mice with clear cell carcinoma cells. [14] Once the 
mice develop tumors, we will inoculate the mice with our neoadjuvant therapy 
intraperitoneally. Since not all of the mice will develop tumors we will use ten mice 
per group in our experiments.  
 
We will start with 20 mice and injecting each mouse intraperitoneally with 1x107 
clear cell carcinoma ovarian cancer cells. [15] (The sample size of 20 was chosen 
based upon the equation for single-group experiments:   n =
logb
log p
 In this equation β 
is the chosen power and p represents the proportion of the animals in the colony 
that are not infected [22]) After 14 days, we will randomize the mice into two 
groups of ten mice in each. Group 1 will begin treatment with the neoadjuvant 
therapy, given once a day, Monday through Friday for one week. The mice in group 2 
and 3 will be treated exactly the same way as the mice in group 1, however group 2 
will be treated with salt water instead of our neoadjuvant therapy and group 3 will 
be treated with our modified nanoparticle without siRNA.  
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Six weeks from the start of the experiment, the mice will be sacrificed in order to 
observe the tumors. The size of the tumors will be monitored and compared 
between both groups. We will also monitor the Sod2 levels in the tumors as well as 
the survival rates between groups. We expect that the tumors in group 2 and 3 will 
be larger and will demonstrate higher levels of Sod2 expression. If these 
expectations hold true then the original hypothesis was correct that this treatment 
would reduce the Sod2 levels, thus slowing down tumor progression. 
 
This experiment will be repeated and modified multiple times over the 6-month 
period. Throughout the in vitro studies, two potential nanoparticle modifications 
were synthesized, GTMA and oxidation, and two potential strands of siRNA, siRNA 
#1 and siRNA #2 were tested. Thus, each modified nanoparticle will be tested with 
each siRNA. Depending on how the mice react to the treatment it may be necessary 
to modify the dosages of the initial clear cell carcinoma cancer cells, as well as the 
dosages of the therapeutic nanocarrier system administered to the mice.  
 
Experiment Injection Total Duration 
Experiment 1: Toxcity 
testing of modified 
BioglycogenTM alone 
GTMA Modification 2 week 
Oxidation Modification 2 week 
Experiment 2: Testing of 
modified BioglycogenTM 
and siRNA 
GTMA + siRNA #1 
Salt Water 
GTMA no siRNA 
6 weeks 
GTMA + siRNA #2 
Salt Water 
GTMA no siRNA 
6 weeks 
Oxidation + siRNA #1 
Salt Water 
Oxidation no siRNA 
6 weeks 
Oxidation + siRNA #2 
Salt Water 
Oxidation no siRNA 
6 weeks 
Table 3: Summary of Phase 1 in vivo Mice Testing  
 
A statistically significant difference between the experimental and the control group 
will determine the success rate of the therapy. The tumors in group 1 should be 
significantly smaller and the Sod2 levels should be significantly lower. The p-levels 
for both of these should be greater than 0.05.  The nanoparticle vehicle and siRNA 
combination that demonstrates the lowest levels of Sod2 and the smallest tumors 
will advance to Phase I FDA Clinical Trials. If the results prove to be consistent with 
expectations then Talamo Inc., will have fulfilled its end of the conditional 
collaboration with Bristol-Myers Squibb.  
 
4. Commercial Potential 
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A. Chemotherapy Market: 
 
The chemotherapy market is currently valued at $42 billion. Experts say that over 
the next ten years this market has staggering growth potential. It is forecasted to 
increase by 17% to $49 billion by 2020. [16] This is an ideal time for this therapy to 
enter the market. Our therapy will be marketed as a neoadjuvant therapy to current 
chemotherapy treatments that are currently on the market. A neoadjuvant therapy, 
in contrast to adjuvant therapy, is given before the main treatment. This 
BioglycogenTM nanoparticle will be marketed as a neoadjuvant drug because it will 
allow the cancer cells to become more responsive to current chemotherapy agents. 
Ultimately, this will increase a patient’s chances for survival and will hopefully 
diminish the pain and agony of ovarian cancer treatments.  
 
There are many factors to account for when considering how much chemotherapy 
will cost the patient. It is important to consider: the types and doses of 
chemotherapy used, how long and how often chemotherapy is given, and where the 
chemotherapy can be administered. Our neoadjuvant therapy will result in 
decreased costs for the patient. The decreased costs are a result of a decrease in the 
size of the chemotherapy doses.  
 
Talamo Inc.’s, CEO, Alex Talamo has spoken to several large pharmaceutical 
companies regarding potential collaborations. Several companies were interested in 
the in vitro results of our nanoparticle. These companies saw great potential in our 
non-toxic modified BioglycogenTM nanoparticle to be a successful neoadjuvant 
therapy. However, each company we approached informed us that they would not 
collaborate with us until we performed in vivo testing in mice. Consequently, it is 
crucial to ensure that our nanoparticle will be non-toxic not only in vito, but also in 
live mice. Thus, it is imperative that we receive the $149,973 from this SBIR grant in 
order to proceed with our in vivo mice testing.  
 
Of all the pharmaceutical companies we corresponded to, Bristol-Myers Squibb was 
the most receptive. Alex Talamo corresponded directly with Francis Cuss the Senior 
Vice President of R&D (since the time of correspondence Mr. Cuss has been 
appointed to Executive Vice President and Chief Scientific Officer, effective July 1st, 
2013). Mr. Cuss is responsible for the discovery and exploratory development of all 
potential new medicines at Bristol-Myers Squibb. Bristol-Myers Squibb has a net 
worth of $39.90 billion (as of April 29th at 5:00 PM) He saw the uniqueness and 
innovation of our technology and believed that our neoadjuvant therapy would 
perform perfectly in combination with the company’s leading chemotherapy drug 
Taxol®. Mr. Cuss has written Talamo Inc., a letter of support.  
 
Taxol® (generic name: paclitaxel), a microtubule inhibitor, is one of the most widely 
used chemotherapy drugs in the world. It has been used to treat over a million 
cancer patients with ovarian, breast, and lung cancer. The mechanism of anticancer 
action of Taxol® involves mitotic arrest of the cells due to microtubule stabilization; 
eventually resulting in apopotosis, cell death. [17] 
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Taxol® gradually loses its effectiveness as tumors develop resistance to it during 
treatment. [17] The mechanism that allows tumors to become resistant to Taxol® is 
not completely understood, there is still ongoing research in this area. Research has 
shown that there are multitudes of survival signaling pathways, which activate the 
chemoresistance in the tumor. [17] Current studies suggest that altered intracellular 
calcium homeostasis may contribute to the Taxol-resistant phenotype. 
 
Our neoadjuvant therapy, in theory, is a potential solution to the gradual resistance 
to Taxol®. Our nanoparticle therapy will be administered to a patient as soon as she 
is diagnosed with ovarian cancer; one of the keys to successful cancer treatment is 
immediate action. Our nanoparticle therapy will inhibit Sod2 expression, which will 
result in decreased tumor progression and increased sensitivity to chemotherapy 
agents. After our particle has been administered to the patient and they agree to 
undergo chemotherapy, they will be given Taxol® which, due to our therapy, will be 
more effective in treating the cancer.  
 
In the pharmaceutical industry and in academia there are many scientists who are 
interested in creating a combinatory therapy with Taxol® and to discover how 
tumors build resistance to it. Currently, NFCR Fellow Susan Band Horwitz, Ph.D., at 
the Albert Einstein College of Medicine, is now exploring why tumor resistance to 
Taxol® occurs and how to make the drug work better. [18] She proposed a 
combinatory drug approach in which a second drug is used to inhibit the activated 
molecular pathway and make the tumor cells regain sensitivity to Taxol®. [19] 
 
Dr. Horwitz’s approach is very interesting and has great promise. However, her plan 
has one major drawback. She wishes to treat the tumor after it has already 
developed a resistance to Taxol®. In the world of cancer time is crucial. Dr. 
Horwitz’s proposed method is reactive instead of proactive and may potentially cost 
a woman her life. Our approach is proactive and will permit a woman extra time to 
battle her ovarian cancer. Our method will hinder the growth of tumor progression 
and increase the sensitivity of Taxol® from the start of the treatment. It is also 
important to note that ovarian cancer is usually detected at an advanced stage due 
to a lack of early symptoms. Thus, our strategy of slowing down the tumor 
progression as soon as possible is a more efficient method to battling ovarian 
cancer, than attempting to force the tumor regain sensitivity to Taxol® after the 
tumor has already developed its protective molecular pathway(s).  
 
B. Competitors: 
 
We are in an interesting situation where our customers may also be our direct 
competitors. Our neoadjuvant therapy increases the effectiveness of current 
chemotherapy drugs, thus the dosing of chemotherapy drugs would be diminished. 
Companies who sell chemotherapy drugs, such as Bristol-Myers Squibb, would not 
make as much profit off of their original drug if they sold it in combination with 
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ours. Consequently, it would be in the pharmaceutical company’s best interest, as 
well as ours, for a collaboration to occur.   
 
Our indirect competitors will be companies who have products that treat the side 
effects of chemotherapy. There will be less of a need for these products once our 
product enters the market and increases the effectiveness of current chemotherapy 
drugs because the dosages of current chemotherapy drugs will be diminished. 
Decreasing the dosages of current chemotherapy drugs will result in less side effects 
and ultimately a decrease in the need to treat the side effects. Common side effects 
for chemotherapy are nausea and vomiting. The most common form of anti-nausea 
medication is a combination of dexamethasone and a serotonin blocker. These 
blockers stop serotonin from sending messages to the brain that trigger nausea. 
Serotonin blockers include dolasetron (Anzemet), granisetron (Kytril and others), 
ondansetron (Zofran and others), and palonosetron (Aloxi). [20] 
 
C. Future Goals: 
 
We project that after 6 months of in vivo testing in mice, our hypothesis will be 
correct and we will have statistically significant data portraying that our particle 
decreased Sod2 expression in the treated group, which resulted in smaller tumors. 
At that point we will begin our collaboration with Bristol-Myers Squibb to 
commence Phase I FDA clinical trials. The $1,000,000 award for phase II of this SBIR 
grant will also be used to proceed to Phase I FDA clinical trials. 
 
Future Funding Sources 
Phase II SBIR- $1,000,000 
Federally Funded Phase III SBIR Awards 
Bristol-Myers Squibb 
Table 4: Future funding sources for Phase I FDA Clinical Trials 
 
After bringing our neoadjuvant therapy to market, we hope to use the profits to fund 
R&D on other cancer cell lines in an attempt to observe which other cancers 
demonstrate high Sod2 levels. Screening of publicly available expression data from 
cancer microarrays indicated that Sod2 expression is consistently elevated in 
bladder cancer specimens. [21] Based upon these findings, it can be inferred that 
there may be other cancers that also demonstrate high Sod2 levels. Once we 
discover other cancers with high Sod2 levels, we wish to test how our neoadjuvant 
therapy would treat those cancers. After we have exhausted all of the cancer types 
that exhibit high Sod2 expression, we would like to use this nanoscale delivery 
technique to deliver other siRNAs to various cancers that exhibit additional 
enzymes which have been proven to increase tumor progression and increased 
chemoresistance.  
 
D. Company Information 
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This company has emerged from a collaborative research initiative between four 
young, hard-working and enthusiastic scientists: Alex Talamo and Sarah Engelberth, 
This is a start-up company, which has substantial industrial potential. Research and 
development are all performed in-house, using our team of multidisciplinary staff. 
Our small size allows our company to focus its time and energy on the design, 
fabrication, and testing of our modified nanoparticle delivery system. 
 
The business objective of Talamo Inc., is to bring non-toxic and extremely efficient 
therapeutic nanocarriers to the market, in order to treat cancer and reduce the 
suffering of humans worldwide. The company has strong R&D capabilities in 
nanoparticle fabrication and in vitro testing with clear cell carcinoma cells. Bristol-
Myers Squibb has an interest in our drug delivery system. They have negotiated a 
conditional collaboration with our company.   
 
Alex Talamo is currently a senior at the College of Nanoscale Science & 
Engineering-University at Albany. He will be graduating in May with a B.Sc(Honors) 
in Nanoscale Science with a concentration in Biology. He is the CEO of this company.  
 
Sarah Engelberth is currently a Ph.D candidate at the College of Nanoscale Science 
& Engineering-University at Albany. She graduated from Ohio Northern University 
with a B.Sc(Honors) in Forensic Biology and Chemistry.   
 
 
5. Consultants and Subawards/Subcontracts 
Dr. Magnus Bergkvist is an Assistant Professor of Nanobioscience at the College of 
Nanoscale Science & Engineering-university at Albany. He obtained his B.Sc. in 
Chemical Engineering from Mälardalen University in Sweden in 1995 and his Ph.D 
in Surface Biotechnology from Uppsala University in Sweden in 2002. His research 
areas are: nanobiotechnology, bionanofabrication, biological structures, 
nanoparticle synthesis, surface chemistry, surface characterization, and atomic force 
microscopy. Dr. Bergkvist oversees the particle synthesis of this research. The 
creation and characterization of the particle was done in his lab using his 
instruments.  
 
Dr. Nadine Hempel is an Assistant Professor of Nanobioscience at the College of 
Nanoscale Science & Engineering-University at Albany. She obtained her 
B.Sc.(Honors) in Pharmacology from the University of Queensland in Australia in 
1999. She obtained her Ph.D. in Pharmacology from the School of Biomedical 
Sciences at the University of Queensland in Australia in 2004. She did her first Post-
doctoral Fellowship at the Department of Hematology and Cancer Biology at Duke 
University Medical Center in 2007. She did her second Post-doctoral Fellowship at 
the Department of Immunology and Microbial Diseases at Albany Medical College in 
2010. She was a Research Assistant Professor at the Department of Immunology and 
Microbial Diseases at Albany Medical College in 2011. She was a Senior Research 
Scientist at the College of Nanoscale Science & Engineering at the University at 
Albany in 2011. Her research areas include: cancer cell metastasis, 
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nanobiotechnology, tumor cell migration and invasion, reactive oxygen species and 
signal transduction, antioxidant enzymes, and tumor markers. Dr. Hempel oversees 
the biological aspects of this project. All cell-based experiments were done in her lab 
using her instruments.  
 
Dr. Antigone McKenna is the Laboratory Animal Resources Director at the 
University at Albany. Dr. McKenna has a doctorate in veterinary medicine. He is the 
primary contact at the University at Albany’s Laboratory Animal Resource center. 
Talamo, Inc. has already discussed our Phase I testing plans with Dr. McKenna. 
These discussions included concerns regarding inoculating the mice via the 
intraperitoneal cavity, how long the experiments would last, and general concerns 
regarding the treatment of the mice. He is in full support of our research efforts and 
has written us a letter of support.   
 
6. Equivalent or Overlapping Proposals to Other Federal Agencies 
 
Talamo, Inc. does not have any other equivalent or overlapping proposals to other 
federal agencies at this time.  
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2011: College of Nanoscale Science & Engineering Summer Intern 
2012-2013: NCAA Student Athlete Tutor 
 
Honors: President’s Award for Leadership, Purple & Gold Award-Emerging Student 
Leader, Chemistry Award for Advanced General Chemistry 
 
Honor Societies: Phi Beta Kappa Honor Society, Omicron Delta Kappa National 
Leadership Honor Society, Presidential Honor Society, and the Honors College 
 
Publications: 
Rajan Kumar, Sheila Smith, James McNeilan, Michael Keeton, Joseph Sanders, Alexander  
Talamo, Christopher Bowman and Yubing Xie. Butterfly wing-inspired 
nanotechnology. In: The Nanobiotechnology Handbook (Y. Xie ed.). Boca Raton, FL, 
CRC Press (in print).  
 
Budget and Budget Justification: 
Sponsor: NSF SBIR   
Title Neoadjuvant Therapy for Ovarian Cancer using 
BioglycogenTM Nanoparticles 
Project Investigator: Dr. Nadine 
Hempel   Co- Project Investigator : Dr. Magnus Bergkvist   
Period of Time: 6 Months           
Year 1         
Salaries % Effort Annual Salary Total Cost 
Requested 
Funding Cost Share 
Faculty           
Dr. Nadine Hempel 15% $100,000  $15,000  $15,000  $0  
Dr. Magnus Bergkvist 17% $83,018  $14,113  $14,113  $0  
      $0  $0  $0  
Total State Paid employees     $29,113 $29,113 $0 
RF Paid Employess           
Alex Talamo 45% $15,000.00  $6,750  $6,750  $0  
      $0  $0  $0  
Total RF Paid Employees     $6,750  $6,750  $0  
Graduate Students FTE         
Sarah Engelberth 50% $21,840.00  $10,920.00  $10,920  $0  
      $0.00  $0  $0  
Total Graduate Students 50%   $10,920  $10,920  $0  
Summer           
      $0  $0  $0  
      $0  $0  $0  
Total Summer Salaries 0%   $0  $0  $0  
Total Salaries     $46,783  $46,783  $0  
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Fringe Benefits Rate % $ Base       
State Employees 50.81% $29,113  $14,792  $14,792  $0  
RF Employees * 45.00% $6,750  $3,038  $3,038  $0  
Graduate Students * 16.00% $10,920  $1,747  $1,747  $0  
Summer 17.00% $0  $0  $0  $0  
Total  Fringe Benefits     $19,577  $19,577  $0  
Total Salaries and Fringe Benefits     $66,360  $66,360  $0  
Other Direct Costs - Attach Details for any item listed below     
Equipment $0  $0  $0  
*Tuition(Half Year) $13,900  $13,900  $0  
Travel $320  $320  $0  
Materials & Supplies $18,257  $18,257  $0  
Publications $4,000  $4,000  $0  
        $0  $0  
        $0  $0  
            
Total Other Direct Costs     $36,477  $36,477  $0  
TOTAL DIRECT COSTS     $102,837  $102,837  $0  
Facilities and Administrative Expense Rate % Base MTDC       
Does not incl:equip, install,tuit 53.00% $88,937  $47,137  $47,137  $0.00  
Total Estimated Project Cost     $149,973  $149,973  $0  
 
Table 3: Budget Report for 6 month Phase 1 Testing 
 
A. Personnel 
 
Dr. Nadine Hempel will spend 15% of her time on the BioglycogenTM nanoparticle 
neoadjuvant therapy testing. This corresponds to a total of $15,000. 
 
Dr. Magnus Bergkvist will spend 17% of his time on the BioglycogenTM nanoparticle 
neoadjuvant therapy testing. This corresponds to $14,113. 
 
Sarah Engelberth will spend 50% of her time on the BioglycogenTM nanoparticle 
neoadjuvant therapy testing. This corresponds to $10,920. Ms. Engelberth is also a 
full time Ph.D. student at the College of Nanoscale Science & Engineering. Her yearly 
tuition will be covered by this grant. This corresponds to $13,900. 
 
Alex Talamo will spend 45% of his time on BioglycogenTM nanoparticle neoadjuvant 
therapy testing. This corresponds to $6,750. 
 
B. Fringe Benefits 
 
Fringe benefits total $19,577. Dr. Nadine Hempel and Dr. Magnus Bergkvist will 
each receive $7,396. Alex Talamo will receive $3,038. Sarah Engelberth will receive 
$1,747. The total fringe benefits will cost $19,577. 
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C. Equipment 
 
The company has already purchased all of the necessary equipment for the 
fabrication of the nanoparticles. Any supplemental instruments are readily 
accessible through other laboratories at the College of Nanoscale Science & 
Engineering or at the University at Albany’s main campus.  
 
D. Travel 
 
After Phase I testing is complete Talamo Inc., will travel to New York, NY, from 
Albany, NY, to report our findings to Francis Cuss at the Bristol-Myers Squibb New 
York office. The price of a 1-way off peak Amtrak ticket is $40. Each member of our 
team will travel to New York and return to Albany. The total cost of travel is $320.  
 
E. Materials and Supplies 
 
1. In-vivo Mice Testing 
Our company will be using the facilities at the University at Albany for its in-
vivo mice testing. The price (per cage, per day) at the uptown campus at the 
University at Albany for state or RF (Research Foundation) funded users is 
$0.55. There are 6 mice per cage. Over the six-month period, the Phase I 
testing will need roughly 400 mice, thus 68 cages will be purchased. The total 
cost of the mice over the six-month period will be $6,732.  
 
2. BioglycogenTM  
Additional BioglycogenTM will be needed in order to create new 
nanoparticles. One kilogram will be sufficient for these experiments. The cost 
of 1 kilogram is $750. 
 
3. Glycidyltrimethylammonium Chloride (GTMA) 
For each kilogram of BioglycogenTM our conjugation requires nine liters of 
GTMA. However, since there are two different modifications that will be 
synthesized from the 1 kg of BioglycogenTM, only 4.5 L of GTMA are required. 
The cost of 4.5 L of GTMA is $2,358. 
 
4. siRNA 
For each kilogram of BioglycogenTM, 6 μmol of siRNA is required. The cost of 
siRNA #1 and siRNA #2 is $418/50 nmol. Our company will purchase 0.5 
μmol of each siRNA. The cost of each siRNA is $4,180/0.5 μmol. The total cost 
of the siRNA is $8,360. Additional siRNA will be created in our laboratory 
using polymerase chain reaction (PCR).  
 
5. Sodium Periodate 
For each kilogram of BioglycogenTM, 50g of sodium periodate is required. 
However, since there are two different modifications that will be synthesized 
 22 
from the 1 kg of BioglycogenTM, only 25 g of sodium periodate will be 
purchased. The cost of 25 g of sodium periodate is $56.70. 
 
F. Publications 
 
The cost of publications, generally, varies from $1,000 to $5,000. The expectation of 
this work to be published is very high. Thus, publication costs are estimated at 
$4,000. This estimation allows us to publish one high profile journal or several 
publications in lower profile journals.  
 
Current and Pending Support: 
 
 No similar proposals have been submitted. 
 
Facilities, Equipment and Other Resources: 
 
Talamo Inc., is affiliated with the University at Albany-College of Nanoscale Science 
& Engineering. The company is able to use all of the state of the art facilities at the 
college. CNSE is located within a 800,000 square foot complex that houses the most 
advanced 200mm/300mm wafer facilities in the academic world, including over 
80,000 square feet of Class 1 capable cleanrooms equipped with 300mm wafer 
processing tools. Talamo Inc., has priority on all of the instruments in both Dr. 
Hempel’s and Dr. Bergkvist’s laboratories. These labs have all of the general 
laboratory equipment needed for cell growth and maintenance, protein chemistry 
and biochemical analysis in the proposed research. The company has access to the 
other laboratories at CNSE that are part of the Nanobioconstellation and can use any 
instrument depending on availability.  
 
Instruments: 
Dynamic Light Scattering 
Fourier Transform Infrared Spectrometer 
 
Dynamic Light Scattering 
A dynamic light scattering (DLS)/zeta potential instrument owned by Dr. Magnus 
Bergkvist will be used to determine the size, polydispersity, distribution, and the 
zeta potential of our synthesized nanoparticles. The DLS instrument records its 
findings by measuring the intensity of light scattered by the nanoparticles as a 
function of time.  
 
Fourier Transform Infrared Spectrometer 
A Fourier Transform Infrared Spectrometer owned by Dr. Magnus Begkvist will be 
used to identify the functional groups present in our synthesized nanoparticles. In 
infrared spectroscopy, IR radiation is passed through a sample. Some of the infrared 
radiation is absorbed by the sample and some of it is transmitted. The resulting 
spectrum represents the molecular absorption and transmission, creating a 
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molecular fingerprint of the sample. No two unique molecular structures produce 
the same infrared spectrum.  
 
The proximity of the CNSE NanoTech complex to the University at Albany main 
campus (10 min walk) is located give access to a range of other shared facilities and 
equipment within the SUNY school system. The life-sciences facilities are located on 
the University at Albany main campus and encompass 194,000 square-feet with 28 
laboratories and biological core facilities. The Laboratory Animal Resources Center 
is a facility at the University at Albany that supports the animal-related needs of 
University researchers, educators, and students. The locations of the proposed SBIR 
research will allow for the completion of Phase I testing and in the future will ensure 
a seamless transition to mass-scale production.  
 
The Phase I research will be split between the labs at CNSE and the Laboratory 
Animal Resource Center at the University at Albany. The particle synthesis will 
occur at CNSE. The in-vivo mice testing will occur at the Laboratory Animal 
Resource Center. Our team has been enrolled in the Occupational Health and Safety 
Program for animal users and is listed on an active, approved IACUC protocol. The 
Facilities Manager also led our team through the Facilities Training, thus granting us 
access to the animal facilities at the University at Albany. 
 
Supplementary Documents: 
 
Talamo Inc., has a letter of support from Francis Cuss, the senior vice president of 
R&D at Bristol-Myers Squibb.  
 
 
 
  
 
